Lupin Launches Generic Aciphex 20 mg Delayed-Release Tablets in US

Pharma Major Lupin Limited (Lupin) announced today that its US subsidiary, Lupin Pharmaceuticals, Inc. (LPI) has launched its generic Rabeprazole Sodium delayed-release tablets, 20mg. Lupin had earlier received final approval from the US FDA for the same. Lupin's Rabeprazole Sodium delayed-release tablets, 20mg, are the generic equivalent of Eisai Inc.'s

Aciphex® delayed-release tablets, 20mg, and are indicated for the treatment of Gastroesophageal reflux disease (GERD). Aciphex® delayed-release tablets, 20mg, had annual U.S sales of approximately US$ 864.3 million (IMS MAT Jun 2013).   About Lupin Limited Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment. Lupin is the 5th largest and fastest growing top 5 generics player in the US (5.3% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales. The Company is also the fastest growing top 10 generic pharmaceutical players in Japan and South Africa (IMS). For the financial year ended March 2013, Lupin's Consolidated turnover and Profit